RecruitingPhase 4

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

Democratic Republic of the Congo, Nigeria3,000 participantsStarted 2024-09-17

Plain-language summary

A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Pregnancy
✕. Breastfeeding
✕. Past serious allergic reaction to study vaccine components
✕. Previous smallpox vaccination
✕. Current or planned use of another investigational drug at any point during study participation

PCR-confirmed Mpox

Timeframe: 8 weeks

Symptom severity

Timeframe: 8 weeks

NCT IDNCT05745987

SponsorMcMaster University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

Mark Loeb, MD